Sacral Neuromodulation for Chronic Pelvic Pain

Launched by WILLIAM BEAUMONT HOSPITALS · Nov 20, 2023

Keywords

ClinConnect Summary

This clinical trial is looking at a treatment called sacral neuromodulation (SNM) for women who suffer from chronic pelvic pain (CPP). SNM is a safe and effective method that has been approved by the FDA for other conditions, and in this study, researchers are trying to see how well it works specifically for managing pelvic pain. To participate, women need to be between the ages of 22 and 70, have had persistent pelvic pain for at least six months, and have tried at least one other form of treatment without success.

Participants in the trial will have a small device implanted that aims to help relieve their pain. Before joining, they must agree to follow all study procedures and not start any new treatments for their pain during the study. It's important to note that women who have had certain medical conditions or treatments, like active pelvic cancer or recent pain management strategies, may not be eligible. If you or someone you know is dealing with chronic pelvic pain and wants to learn more about this trial, it could be a valuable opportunity to explore a new treatment option.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • 1. Provision of signed and dated informed consent form
• • 2. Stated willingness to comply with all study procedures and availability for the duration of the study
• • 3. Female, aged 22-70
• • 4. Chronic pelvic pain (= pain below umbilicus) score of 4 or greater on 10-point VAS, present for 6 months or greater (screening patient)
• • 5. Failed at least 1 or more conservative treatments (e.g. pelvic floor physical therapy, biofeedback, behavioral modification, oral pharmacotherapy, bladder instillations)
• • 6. No changes to current regimen of medications for their pelvic pain for \> 4 weeks prior to screening
• • 7. For females of reproductive potential: use of highly effective contraception (e.g. licensed hormonal or barrier methods), for at least 1 month prior to screening and agreement to use such a method during study participation
• • 8. Participant agrees not to start any new treatment interventions for CPP prior to Visit 4 (Primary Endpoint)
• Exclusion Criteria:
• • 1. History of any active pelvic cancer
• • 2. Any significant medical condition that is likely to interfere with study procedures, device operation, or likely to confound evaluation of study endpoints
• • 3. Concurrent pain management strategies within the past 3 months that may interfere or mask study intervention (e.g. pelvic floor physical therapy, shockwave therapy, trigger point injections, bladder instillations)
• • 4. Any psychiatric or personality disorder at the discretion of the study physician. This does not include depression or generalized anxiety disorders that are stable.
• • 5. Current symptomatic urinary tract infection (UTI) or more than 6 UTIs in past year
• • 6. Severe or uncontrolled diabetes (A1C \> 7, documented in the last 3 months) or diabetes with peripheral nerve involvement
• • 7. Interstitial cystitis diagnosis with Hunner's lesions as this is a severe inflammatory bladder condition that can only be treated with eradication of the lesions or a cystectomy. SNM would be be expected to help for IC with Hunner's lesions
• • 8. Previously implanted with a sacral neuromodulation device or participated in a sacral neuromodulation trial
• • 9. Subject with documented history of allergy to titanium, zirconia, polyurethane, epoxy, or silicone
• • 10. Implantation of spinal cord stimulator and/or drug delivery pumps, whether turned on or off
• • 11. A female who is breastfeeding or of child-bearing potential with a positive urine pregnancy test or not using adequate contraception
• • 12. Current treatment for active malignancy (skin cancers excluded)
• • 13. Patients with spinal pathology that could confound study results. This may include participants with cauda equina syndrome, spinal stenosis, neurogenic claudication, lumbar radiculopathy, patients with primary complaints of leg pain with numbness and or weakness, patients with a primary pain compliant that is vascular in origin, clinical evidence of progressive neurologic pathology, mechanical instability or other spinal pathology that requires surgical intervention, spine or visceral pain secondary to neoplasm, visceral pain in the upper abdomen rather than the pelvis, current diagnosis of fibromyalgia participants with significant cognitive impairment, participants with a condition currently requiring or likely to require use of diathermy or MRI or history of any other condition that in the opinion of the investigator could put the participant at risk or interfere with study results interpretation. (screening patient).
• • 14. Participants involved in ongoing litigation and or injury claims or workers compensation claims.
• • 15. Participation in a current clinical trial or within the preceding 30 days
• • Note- to preserve the scientific integrity of the study some criteria have been omitted from this posting. All eligibility criteria will be listed at the close of the study.